ARTA
ROSG

A.R.T. Advisors’s Rosetta Genomics Ltd. ROSG Stock Holding History

A.R.T. Advisors’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,374
Closed -$37K – 1867
2014
Q4 		$37K Buy
+1,374
New +$44.6K ﹤0.01% 1359

Other funds holding ROSG

HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

A.R.T. Advisors's ROSG Position: Q1 2015 in Review

A.R.T. Advisors sold out of Rosetta Genomics Ltd. (ROSG) in Q1 2015, closing a stake of 1,374 shares — an estimated $37K sold.

A.R.T. Advisors first reported a position in ROSG in Q4 2014 and held it in 1 quarter. The position peaked at $37K in Q4 2014. 12 funds tracked by Wall St. Rank hold ROSG as of Q1 2015.

  • A.R.T. Advisors reported no remaining Rosetta Genomics Ltd. position as of Q1 2015 after selling out during the quarter.
  • A.R.T. Advisors sold 1,374 Rosetta Genomics Ltd. shares in Q1 2015, an estimated $37K.
  • A.R.T. Advisors first reported a position in Rosetta Genomics Ltd. in Q4 2014 and held it in 1 quarter.
  • A.R.T. Advisors's Rosetta Genomics Ltd. position peaked at $37K in Q4 2014.
  • 12 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q1 2015.

Based on A.R.T. Advisors's 13F filing for Q1 2015, filed 15 May 2015.